Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.20 per share which missed the analyst consensus estimate of $1.32 by 9.09 percent. This is a 160.87 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $88.18 million which missed the analyst consensus estimate of $96.24 million by 8.37 percent. This is a 94.88 percent increase over sales of $45.25 million the same period last year.